Serological Responses to Influenza Vaccination during Pregnancy

Vazquez-Pagan, Ana; Schultz‐Cherry, Stacey

doi:10.3390/microorganisms9112305

Cited by 5 publications

(3 citation statements)

References 87 publications

(197 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of pregnancy on host immunity has long been appreciated as alterations during the gestational period, such as changes in hormones or the inflammatory secretome, can alter broad immune responses to infection, and immunization with a split-inactivated influenza vaccine. 36–39 Our study extends this work and demonstrates variable outcomes depending on which influenza vaccine platform was used to immunize pregnant dams ( Figure 1 ). While all vaccinated or previously infected groups exhibited improved protection from a lethal influenza challenge, LAIV and rHA vaccination along with IAV infection resulted in a significantly increased chance of survival ( Figure 1H ), a result that aligned with the quantity ( Figure 1B ) and quality of antibody levels in these groups ( Figure 1D ).…”

Section: Discussionsupporting

confidence: 72%

“…Given the difficulties in performing extensive vaccine studies with longitudinal sampling in pregnant women, mouse models of pregnancy have provided an opportunity to better understand the elicitation of humoral responses during pregnancy upon infection or vaccination. 36 However, available preclinical studies still provide limited information on how additional influenza vaccine platforms may influence immunogenicity in dams and subsequently, passive immunity in their offspring. Here, we sought to investigate the efficacy and immunogenicity of distinct influenza vaccine platforms provided during pregnancy along with the kinetics and functionality of passively transferred matAbs.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Maternal immunization with distinct influenza vaccine platforms elicits unique antibody profiles that impact the protection of offspring

Vazquez-Pagan,

Roubidoux,

Cherry

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Pregnant women and infants are considered high-risk groups for increased influenza disease severity. While influenza virus vaccines are recommended during pregnancy, infants cannot be vaccinated until at least six months of age. Passive transfer of maternal antibodies (matAbs) becomes vital for the infant’s protection. Here, we employed an ultrasound-based timed-pregnancy murine model and examined matAb responses to distinct influenza vaccine platforms and influenza A virus (IAV) infection in dams and their offspring. We demonstrate vaccinating dams with a live-attenuated influenza virus (LAIV) vaccine or recombinant hemagglutinin (rHA) proteins administered with adjuvant resulted in enhanced and long-lasting immunity and protection from influenza in offspring. In contrast, a trivalent split-inactivated vaccine (TIV) afforded limited protection in our model. By cross-fostering pups, we show the timing of antibody transfer from vaccinated dams to their offspring (prenatal versus postnatal) can shape the antibody profile depending on the vaccine platform. Our studies provide information on how distinct influenza vaccines lead to immunogenicity and efficacy during pregnancy, impact the protection of their offspring, and detail roles for IgG1 and IgG2c in the development of vaccine administration during pregnancy that stimulate and measure expression of both antibody subclasses.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Discussionmentioning

confidence: 99%

Maternal immunization with distinct influenza vaccine platforms elicits unique antibody profiles that impact the protection of offspring

Vazquez-Pagan,

Roubidoux,

Cherry

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…This is accompanied by higher incidence of preeclampsia, IUGR, gestational diabetes. The latter appears to be related to immunotolerance and here we see how the immune suppression impair an effective Anti-S-IgG protection 5,6,23,24 .…”

Section: Discussionmentioning

confidence: 60%

Vaccination in twin pregnancies: comparison between immunization before conception and during pregnancy

Svirsky,

Rabbi,

Hamad

et al. 2024

Sci Rep

View full text Add to dashboard Cite

To evaluate the development of neutralizing Anti-Spike Protein IgG (Anti-S-IgG) during twin pregnancies before conception vs. during pregnancy. In this prospective study, three blood samples were collected from pregnant women and subjected to anti-S-IgG immunodiagnostics. The patient’s medical records, including vaccination and PCR test results, were collected from the hospital’s electronic database. Age-matched non-pregnant women were used as a control group. We enrolled 83 women with twin pregnancies. 49 women were vaccinated before conception, 21 women were vaccinated during pregnancy, and 13 were not vaccinated. Of the 13 women who weren’t vaccinated, three became positive during pregnancy, and all three were severely ill. By contrast, in women who were vaccinated during or before pregnancy, COVID-19 infection during pregnancy caused only mild symptoms. A ten-fold lower level of neutralizing Anti-S-IgG in the 3rd trimester was observed in healthy women who were vaccinated before conception and remained healthy until discharge from the hospital after delivery 1605 (IQR: 763–2410) compared to the healthy women who were vaccinated during pregnancy 152 AU/mL (IQR: 54–360). This difference was higher among women who were infected by COVID-19 (as verified by a positive PCR test). The third-trimester level of neutralizing Ant-S-IgG in the infected group was 4770 AU/mL (4760–6100) in infected women vaccinated before conception compared to those vaccinated during pregnancy who had 70 AU/mL (IQR: 20–170) (p < 0.001). In women vaccinated at 13–16 weeks gestation, neutralizing Anti-S-IgG at 20–22 weeks went up to 372 AU/mL (IQR: 120–1598) but rapidly dropped to 112 AU/mL (IQR: 54–357) at 28–30 weeks, (p < 0.001), a faster decline than in women vaccinated at a median 22 weeks before conception. Being infected by COVID-19 before conception was linked to having low Anti-S-IgG levels during pregnancy, whereas being infected by COVID-19 during pregnancy led to a very high response in the 3rd trimester. In twin pregnancies, significantly lower neutralizing Anti-S-IgG levels were observed in women vaccinated during pregnancy compared to those vaccinated before conception, whether infected or not infected by COVID-19. A full course of vaccination before conception is recommended.Trial registration. ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: October 4, 2021. https://clinicaltrials.gov/ ID: NCT04595214.

show abstract

Maternal influenza vaccination and child mortality: Longitudinal, population-based linked cohort study

Foo

Sarna

Pereira

et al. 2022

Vaccine

View full text Add to dashboard Cite

Serological Responses to Influenza Vaccination during Pregnancy

Cited by 5 publications

References 87 publications

Maternal immunization with distinct influenza vaccine platforms elicits unique antibody profiles that impact the protection of offspring

Maternal immunization with distinct influenza vaccine platforms elicits unique antibody profiles that impact the protection of offspring

Vaccination in twin pregnancies: comparison between immunization before conception and during pregnancy

Maternal influenza vaccination and child mortality: Longitudinal, population-based linked cohort study

Contact Info

Product

Resources

About